touchCARDIO spoke to Dr Duk-Woo Park (Asan Medical Center, Seoul, South Korea) to discuss his presentation at the American College of Cardiology Annual Meeting 2022, providing the results of the ADAPT-TAVR trial of edoxaban versus dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after transcatheter aortic-valve replacement. (To view Part Two click here)
Questions
- What are the limitations of current antithrombotic strategies following transcatheter aortic valve replacement (TAVR)? 00:20-01:52
- What is known about the benefits of non-vitamin K antagonist oral anticoagulants following TAVR? 01:52-02:58
Speaker Disclosure: Duk-Woo Park discloses institutional research grants from Boston scientific, Abbott and Philips.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
